The aumolertinib dose was then increased to the standard 110 mg daily and treatment was continued.<h4>Conclusion</h4>Rechallenging with an EGFR-TKI after osimertinib-induced ILD remains highly challenging, particularly for grade 3 or higher ILD. Here, EGFR is linked to interstitial lung disease.